Targeting DVL by inhibiting DVL/FZD interaction via a KTXXXW-containing peptide was reported to inactivate the canonical Wnt/β-catenin pathway, leading to cell death of HCC cells. This evidence concerns the gene DVL1 and hepatocellular carcinoma.